CHC
NBIX icon

City Holding Co’s Neurocrine Biosciences NBIX Stock Holding History

City Holding Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.9K Hold
100
– – ﹤0.01% 459
2026
Q1 		$13.2K Hold
100
– – ﹤0.01% 446
2025
Q4 		$14.2K Hold
100
– – ﹤0.01% 450
2025
Q3 		$14K Hold
100
– – ﹤0.01% 453
2025
Q2 		$12.6K Hold
100
– – ﹤0.01% 406
2025
Q1 		$11.1K Hold
100
– – ﹤0.01% 480
2024
Q4 		$13.7K Hold
100
– – ﹤0.01% 390
2024
Q3 		$11.5K Buy
+100
New +$13.7K ﹤0.01% 396

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

City Holding Co's NBIX Position: Q2 2026 in Review

City Holding Co held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 100 shares worth $16.9K. The position accounts for ﹤0.01% of the portfolio, ranked #459.

City Holding Co first reported a position in NBIX in Q3 2024 and has held it in 8 quarters since. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • City Holding Co held 100 shares of Neurocrine Biosciences worth $16.9K as of Q2 2026.
  • City Holding Co left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of City Holding Co's portfolio in Q2 2026, its #459 holding.
  • City Holding Co first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 8 quarters since.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on City Holding Co's 13F filing for Q2 2026, filed 10 Jul 2026.